MDT

100.71

-0.28%↓

135.73

+0.63%↑

VEEV

223.72

+0.88%↑

HQY

85.01

+1.03%↑

NEOG

+1.94%↑

MDT

100.71

-0.28%↓

135.73

+0.63%↑

VEEV

223.72

+0.88%↑

HQY

85.01

+1.03%↑

NEOG

+1.94%↑

MDT

100.71

-0.28%↓

135.73

+0.63%↑

VEEV

223.72

+0.88%↑

HQY

85.01

+1.03%↑

NEOG

+1.94%↑

MDT

100.71

-0.28%↓

135.73

+0.63%↑

VEEV

223.72

+0.88%↑

HQY

85.01

+1.03%↑

NEOG

+1.94%↑

MDT

100.71

-0.28%↓

135.73

+0.63%↑

VEEV

223.72

+0.88%↑

HQY

85.01

+1.03%↑

NEOG

+1.94%↑

Home・Akcijų sąrašas・Lisata Therapeutics

L
Lisata Therapeutics

Uždarymo kaina

4.07 -0.73

Pirkti Parduoti

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

4.03

Max

4.1

Pagrindiniai rodikliai
By Trading Economics
Darbuotojai	26

Dividendai
By Dow Jones
Kitas uždarbis	2026-02-26

Rinkos statistika
By TradingEconomics
Rinkos kapitalizacija	-4.2M 16M
Ankstesnė atidarymo kaina	4.8
Ankstesnė uždarymo kaina	4.07

Lisata Therapeutics Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2026-01-26 23:49; UTC

Karštos akcijos

Stocks to Watch: Agilysys, Nucor, Humana, UnitedHealth

2026-01-26 23:09; UTC

Pagrindinės rinkos jėgos

Health Insurers' Shares Fall After Government Proposes Flat Medicare Advantage Rate

2026-01-26 23:52; UTC

Rinkos pokalbiai

Gold's Path of Least Resistance Still Looks Higher, Technical Analysis Shows -- Market Talk

2026-01-26 23:46; UTC

Rinkos pokalbiai

Nikkei May Decline as Yen's Rebound Raises Caution Over Earnings -- Market Talk

2026-01-26 23:37; UTC

Rinkos pokalbiai

Gold Rises Amid Concerns Over Tariffs -- Market Talk

2026-01-26 22:41; UTC

Rinkos pokalbiai

Australian 4Q CPI To Provide Smoking Gun For Hike -- Market Talk

2026-01-26 22:26; UTC

Uždarbis

Karoon Expects Capex of US$110 Million-US$135 Million in 2026

2026-01-26 22:26; UTC

Uždarbis

Karoon Expects Operating Costs to Fall Once Transition of Bauna FPSO Operatorship Completes

2026-01-26 22:25; UTC

Uždarbis

Karoon Energy Expects Unit Production Cost of US$12-US$15/BOE in 2026

2026-01-26 22:25; UTC

Uždarbis

Karoon Energy Expects Output to Rise in 2H Following Bauna Investment Program

2026-01-26 22:25; UTC

Uždarbis

Karoon Energy Expects Output of 8.1 Million-9.2 Million BOE in 2026

2026-01-26 22:24; UTC

Uždarbis

Karoon Energy 4Q Sales Revenue US$156.1 Million

2026-01-26 22:23; UTC

Uždarbis

Karoon Energy 4Q Sales Volumes 2.65 Million BOE, Up 5% on Quarter

2026-01-26 22:23; UTC

Uždarbis

Karoon Energy: Bauna FPSO Efficiency Increased to 98.8%

2026-01-26 22:23; UTC

Uždarbis

Karoon Energy FY Oil, Natural Gas Production 10.3 Million BOE

2026-01-26 22:22; UTC

Uždarbis

Karoon Energy 4Q Oil, Natural Gas Production 2.37 Million BOE

2026-01-26 22:05; UTC

Įsigijimai, susijungimai, perėmimai

Fortescue: Alta Copper Shareholders Approve Takeover

2026-01-26 22:02; UTC

Įsigijimai, susijungimai, perėmimai

Senate Antitrust Panel Chair Raises Concerns Over Netflix-Warner Deal -- WSJ

2026-01-26 21:50; UTC

Rinkos pokalbiai

Uždarbis

Financial Services Roundup: Market Talk

2026-01-26 21:50; UTC

Rinkos pokalbiai

Auto & Transport Roundup: Market Talk

2026-01-26 21:34; UTC

Uždarbis

Nucor: Steel Products Segment Expected Improved Earnings in 1Q Due to Increased Volumes on Stable Pricing >NUE

2026-01-26 21:34; UTC

Uždarbis

Nucor: Steel Mills Segment Expected Increase Is Due to Higher Volumes and Higher Realized Prices Across All Major Pdt Categories >NUE

2026-01-26 21:34; UTC

Uždarbis

Nucor: Raw Materials Segment Is Expected to Have Increased Earnings in 1Q >NUE

2026-01-26 21:34; UTC

Uždarbis

Nucor: 1Q Earnings Expected to Increase Across All Three Operating Segments, With the Largest Increase in Steel Mills Segment >NUE

2026-01-26 21:30; UTC

Įsigijimai, susijungimai, perėmimai

Eaton Stock Rises on Spin-Off Plan. Why It's Going All-In on Planes and AI Data Centers. -- Barrons.com

2026-01-26 21:30; UTC

Uždarbis

Nucor 4Q Sales $7.69B >NUE

2026-01-26 21:30; UTC

Uždarbis

Nucor 4Q Net $378M >NUE

2026-01-26 21:30; UTC

Uždarbis

Nucor 4Q Steel Mills Total Shipments 5.91M Tons >NUE

2026-01-26 21:30; UTC

Uždarbis

Nucor 4Q Total Tons Shipped to Outside Customers Down 9% >NUE

2026-01-26 21:30; UTC

Uždarbis

Nucor 4Q EPS $1.64 >NUE

Akcijų palyginimas

Kainos pokytis

Lisata Therapeutics Prognozė

Bendras įvertinimas

By TipRanks

Neutralu

1 ratings

Pirkti

Laikyti

Parduoti

Remiantis 1 analitikų, pateikusių Lisata Therapeutics akcijų reitingus – Dist per pastaruosius 3 mėnesius.

Finansinės naujienos

Apie bendrovę Lisata Therapeutics

Lisata Therapeutics, Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of innovative therapies for the treatment of solid tumors and other diseases. Its product candidates include LSTA1, which is in Phase 2a and 2b clinical studies for the treatment of solid tumor, including metastatic pancreatic ductal adenocarcinoma (mPDAC), in combination with a range of anti-cancer regimens; XOWNA that is in Phase IIa clinical trial for the treatment of coronary microvascular dysfunction; and CD34+ cell therapy for the treatment of chronic kidney disease. Lisata Therapeutics, Inc. was incorporated in 1980 and is headquartered in Basking Ridge, New Jersey.